Ecteinascidins (Et's), isolated from the Caribbean tunicate Ecteinascidia turbinata, protect mice in vivo against P388 lymphoma, B16 melanoma, M5076 ovarian sarcoma, Lewis lung carcinoma, and the LX-1 human lung and MX-1 human mammary carcinoma zenografts.
The present invention is directed to a synthetic process for the formation of ecteinascidin compounds and related structures, such as the saframycins. In one particularly preferred embodiment, the present invention provides a synthetic route for the formation of ecteinascidin 743 (1), ##STR1## an exceedingly potent and rare marine-derived antitumor agent which is slated for clinical trials. The process of this invention is enantio- and stereocontrolled, convergent and short. Also disclosed are novel process intermediates, useful not only in the total synthesis of ecteinascidin 743, but also other known ecteinascidin compounds, including derivatives and analogs thereof.
Ecteinascidins (Et's), isolated from the Caribbean tunicate Ecteinascidia turbinata, protect mice in vivo against P388 lymphoma, B16 melanoma, M5076 ovarian sarcoma, Lewis lung carcinoma, and the LX-1 human lung and MX-1 human mammary carcinoma zenografts.
The present invention is directed to the synthesis and characterization of compounds having the formula: ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8 and R.sub.9 are each independently selected from the group consisting of H, OH, OR', SH, SR', SOR', SO.sub.2 R', NO.sub.2, NH.sub.2, NHR', N(R').sub.2, NHC(O)R', CN, halogen, .dbd.O, C(.dbd.O)H, C(.dbd.O)R', CO.sub.2 H, CO.sub.2 R', C.sub.1 -C.sub.12 alkyl, C.sub.2 -C.sub.12 alkenyl, C.sub.2 -C.sub.12 alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, and substituted or unsubstituted heteroaromatic; wherein each of the R' groups is independently selected from the group consisting of H, OH, NH.sub.2, NO.sub.2, SH, CN, halogen, .dbd.O, C(.dbd.O)H, C(.dbd.O)CH.sub.3, CO.sub.2 H, CO.sub.2 CH.sub.3, C.sub.1 -C.sub.12 alkyl, C.sub.2 -C.sub.12 alkenyl, C.sub.2 -C.sub.12 alkynyl, aryl, aralkyl, and heteroaromatic; wherein each dotted circle represents one, two or three optional double bonds; wherein R.sub.7 and R.sub.8 may be joined into a carbocyclic or heterocyclic ring system; and wherein X.sub.1 and X.sub.2 are each independently defined as above for R.sub.1 -R.sub.8, and each further includes specific preferred groups as defined herein.
The present invention is directed to the synthesis and characterization of compounds having the formula: ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8 and R.sub.9 are each independently selected from the group consisting of H, OH, OR', SH, SR', SOR', SO.sub.2 R', NO.sub.2, NH.sub.2, NHR', N(R').sub.2, NHC(O)R', CN, halogen, .dbd.O, C(.dbd.O)H, C(.dbd.O)R', CO.sub.2 H, CO.sub.2 R', C.sub.1 -C.sub.12 alkyl, C.sub.2 -C.sub.12 alkenyl, C.sub.2 -C.sub.12 alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, and substituted or unsubstituted heteroaromatic; wherein each of the R' groups is independently selected from the group consisting of H, OH, NH.sub.2, NO.sub.2, SH, CN, halogen, .dbd.O, C(.dbd.O)H, C(.dbd.O)CH.sub.3, CO.sub.2 H, CO.sub.2 CH.sub.3, C.sub.1 -C.sub.12 alkyl, C.sub.2 -C.sub.12 alkenyl, C.sub.2 -C.sub.12 alkynyl, aryl, aralkyl, and heteroaromatic; wherein each dotted circle represents one, two or three optional double bonds; wherein R.sub.7 and R.sub.8 may be joined into a carbocyclic or heterocyclic ring system; and wherein X.sub.1 and X.sub.2 are each independently defined as above for R.sub.1 -R.sub.8, and each further includes specific preferred groups as defined herein.
The present invention is directed to the synthesis and characterization of compounds having the formula: wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8 and R.sub.9 are each independently selected from the group consisting of H, OH, OR', SH, SR', SOR', SO.sub.2 R', NO.sub.2, NH.sub.2, NHR', N(R).sub.2, NHC(O)R', CN, halogen, .dbd.O, C(.dbd.O)H, C(.dbd.O)R', CO.sub.2 H, CO.sub.2 R', C.sub.1 -C.sub.12 alkyl, C.sub.2 -C.sub.12 alkenyl, C.sub.2 -C.sub.12 alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, and substituted or unsubstituted heteroaromatic; wherein each of the R' groups is independently selected from the group consisting of H, OH, NH.sub.2, NO.sub.2, SH, CN, halogen, .dbd.O, C(.dbd.O)H, C(.dbd.O)CH.sub.3, CO.sub.2 H, CO.sub.2 CH.sub.3, C.sub.1 -C.sub.12 alkyl, C.sub.2 -C.sub.12 alkenyl, C.sub.2 -C.sub.12 alkynyl, aryl, aralkyl, and heteroaromatic; wherein each dotted circle represents one, two or three optional double bonds; wherein R.sub.7 and R.sub.8 may be joined into a carbocyclic or heterocyclic ring system; and wherein X.sub.1 and X.sub.2 are each independently defined as above for R.sub.1 -R.sub.8, and each further includes specific preferred groups as defined herein.
